Megestrol 40 mg tablets are used for the palliative treatment of advanced breast cancer and advanced endometrial cancer. Specifically, they’re approved for cases where the cancer is recurrent, inoperable, or has spread to other parts of the body. The 40 mg tablet form is distinct from the liquid suspension version of the same drug, which serves a completely different purpose. Understanding which form does what, and how the tablet works in cancer treatment, helps clarify why your doctor may have prescribed or discussed it.
How the 40 mg Tablet Differs From the Liquid Form
Megestrol comes in two forms that treat very different conditions. The 40 mg tablet is specifically for advanced breast or endometrial cancer. The oral suspension (liquid) is prescribed to treat severe weight loss, malnutrition, and appetite loss in people with AIDS. If you’ve seen megestrol described as an “appetite stimulant,” that applies only to the liquid form at much higher doses, not the 40 mg cancer tablet.
Breast Cancer Treatment
For advanced breast cancer, the standard dose is 40 mg taken four times a day, totaling 160 mg daily. Treatment typically continues for at least two months before doctors assess whether the cancer is responding. This is considered a palliative treatment, meaning it aims to slow the disease and reduce suffering rather than cure the cancer. It’s not meant to replace surgery, radiation, or chemotherapy, but rather to serve as an additional or alternative option when those treatments aren’t viable.
Megestrol works particularly well in cancers that are sensitive to hormones. It mimics progesterone, a natural hormone, and activates progesterone receptors in reproductive tissue. One of its key effects is blocking a hormonal signal from the pituitary gland that normally triggers estrogen release from the ovaries. Without that estrogen supply, hormone-dependent tumor cells lose a major growth signal. Current NCCN guidelines continue to recommend hormone-based therapies like megestrol as a treatment option for hormone receptor-positive cancers.
Endometrial Cancer Treatment
For advanced endometrial cancer (cancer of the uterine lining), European guidelines recommend megestrol at 160 mg daily, which works out to four 40 mg tablets per day. Like its use in breast cancer, megestrol targets endometrial tumors that rely on hormonal signals to grow. By shifting the hormonal environment, it can slow or stabilize disease progression in recurrent or metastatic cases.
A 2026 case report published in Frontiers in Oncology documented a patient with metastatic endometrial cancer who achieved disease control for over nine years using megestrol combined with another hormonal agent. While that’s an exceptional case, it illustrates the potential for long-term benefit in some patients. Megestrol is not recommended for other types of cancer beyond breast and endometrial.
Common Side Effects
Clinical trial data from patients taking megestrol 40 mg four times daily give a clear picture of what to expect. Fatigue is the most frequently reported side effect, affecting about 29% of patients. Shortness of breath occurs in roughly 15%, and pain in about 13%. Nausea and abdominal pain each affect around 11 to 12% of patients.
Mood-related effects are fairly common as well. About 11% of patients experience anxiety, 9% report depression, and 9% deal with insomnia. Digestive issues like constipation (8%), diarrhea (5%), and vomiting (4%) also show up in trial data. Increased sweating affects about 9% of patients, and headaches occur in roughly 7%.
Weight gain is a notable concern. In a comparative trial of postmenopausal women with advanced breast cancer, 17% of those taking megestrol gained more than 10% of their baseline body weight. That’s roughly double the rate seen with other hormonal treatments in the same study. Some of this weight gain may relate to increased appetite, which occurs in about 6% of patients on the 40 mg dose.
Blood Clot Risk and Other Warnings
Megestrol carries a risk of blood clots, including deep vein thrombosis (clots in the legs) and pulmonary embolism (clots in the lungs). If you have a history of blood clots or related conditions, your doctor will weigh that risk carefully. Postmarketing reports have also flagged problems with blood sugar regulation in some patients.
The drug is classified as Pregnancy Category X, meaning it can cause harm to a developing fetus and should never be taken during pregnancy. It’s also contraindicated if you have a known allergy to megestrol or any inactive ingredient in the tablet.
What to Expect During Treatment
Because megestrol is a palliative therapy, the goal is managing the disease rather than eliminating it. You’ll typically take four tablets spread throughout the day. Your oncologist will monitor your response over the first couple of months and adjust the plan based on how your cancer behaves, how you’re tolerating the medication, and whether side effects are manageable. Treatment can continue for months or, in some cases, years if the cancer remains stable and the side effects are acceptable.
If you experience sudden leg swelling, chest pain, or difficulty breathing, those could signal a blood clot and need immediate medical attention. Routine monitoring for weight changes and blood sugar levels is also common during treatment.